A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis



Status:Completed
Conditions:Neurology, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery, Neurology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:March 2012
End Date:June 2015

Use our guide to learn which trials are right for you!

A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS

This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group
study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients
with systemic sclerosis. Patients will be randomized to receive either RoActemra/Actemra 162
mg subcutaneously weekly or placebo for 48 weeks. From Week 49 to Week 96, all patients will
receive open-label RoActemra/Actemra 162 mg subcutaneously weekly. Anticipated time on study
treatment is 96 weeks.


Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Systemic sclerosis, as defined by American College of Rheumatology (1980) criteria

- Disease duration of manifestation)

- >/= 15 and
- Active disease, as defined by protocol

- Uninvolved skin at injection sites

- Negative pregnancy test for a female subject of childbearing potential

Exclusion Criteria:

- Major surgery (including joint surgery) within 8 weeks prior to and/or during study
enrollment

- Rheumatic autoimmune disease other than systemic sclerosis

- Skin thickening (scleroderma) limited to areas distal to the elbows or knees at
screening

- Previous treatment with tocilizumab

- History of severe allergic or anaphylactic reactions to human, humanized, or murine
monoclonal antibodies

- Severe cardiopulmonary disease

- Known active current or history of recurrent infections

- Use of any investigational, biologic, or immunosuppressive therapies including
intra-articular or parenteral corticosteroids prior to study enrollment as specified
in the protocol

- As specified in the protocol, any current or past medical condition or medical
history involving but not limited to the nervous, renal, pulmonary, endocrine, and
gastrointestinal organ systems determined by the Principal Investigator to pose a
significant safety risk to any subject while participating in the study

- Primary or secondary immunodeficiency
We found this trial at
22
sites
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Farmington, CT
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
?
mi
from
London,
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Stanford, CA
Click here to add this to my saved trials
?
mi
from
Toledo, OH
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials